How Bristol Myers Squibb Pays
Bristol Myers Squibb's EG80 to EG180 enterprise-grade ladder from Analyst to Vice President, priced across 30 markets in 16 countries alongside PSU, MSU and RSU equity, a $21.88M chief executive package at a 131:1 ratio, and 247 certified FY2025 H-1B applications.
Band Hierarchy
Bristol Myers Squibb publishes no enterprise-grade catalogue. Official job material confirms the EG80 and EG90 rungs, including Analyst II and Senior Associate Scientist postings, and posted salary ranges anchor Associate Director through Senior Director. Everything between EG100 and EG180 is employee-reported and conflicting, and the Senior Vice President and Executive Vice President layer is a proxy disclosure rather than a numbered grade.
Professional ladder — EG80 through EG100
Dual track — EG110 through EG130
Leadership ladder — EG140 through EG160
Executive ladder — EG170 and EG180
Disclosed executive layer
Track divergence
Hierarchy qualifications and legacy structures
- Do not use the enterprise grade alone to price a role. Title scope, function, location and the posted salary range are far more reliable than an anonymous grade map, and BMS posts ranges in several United States states and in Poland.
- Software engineering is not a separate public ladder. Digital and technology titles sit inside the same enterprise-grade framework, and no BMS-specific staff, principal or distinguished engineer ladder was found in any reviewed source.
- Legacy Celgene integration is visible in the equity plans, not in a disclosed employee-grade conversion table. The 2014 and 2017 Celgene plans were assumed in the 2019 acquisition and later closed to new grants, but a legacy-band harmonisation schedule is Not publicly disclosed.
- The Senior Vice President and Executive Vice President layer is a corporate officer designation rather than a numbered grade, so this report keeps it in the executive section instead of extending the band ladder into it.
- Board directors are outside the employee ladder. Non-employee directors receive cash retainers and deferred share units under a separate structure, and no director row appears in the band chart.
Peer-level mapping
| Band | Archetype | Peer mapping | Caveat |
|---|---|---|---|
| EG80 | Analyst / Specialist / Associate | Merck and Pfizer entry professional, generic P1 | Scope-based orientation only; BMS publishes no peer-level crosswalk.Employee-reported Princeton and Lawrenceville entry pay; equity is a real zero because no recurring grant is evidenced at this grade. |
| EG90 | Senior Analyst / Senior Specialist / Associate Scientist | Experienced professional, generic P2 | The only grade below EG100 confirmed in official BMS job material.Current BMS Workday postings naming Analyst II and Senior Associate Scientist at the EG90 grade. |
| EG100 | Lead / Analyst III / Manager | Senior professional or first-line manager | First-line manager titles start appearing here, but the mapping varies by function.Employee-reported grade clues plus an Indeed manager average of $119,162 across mixed United States worksites. |
| EG110 | Manager II / Associate Manager / Principal Specialist | Lead professional or M1 | Principal technical roles and Manager II titles coexist at this grade.Employee-reported grade mapping interpolated between the EG100 and EG120 anchors. |
| EG120 | Senior Manager | M2 or senior professional | The clearest dual-track grade; scientific principals sit alongside people managers.Indeed senior manager average of $153,972 across mixed United States worksites, cross-checked against Levels.fyi records. |
| EG130 | Senior Manager II / Group Lead | M3 or principal professional | Modelled between the EG120 observation and the EG140 posted range.Modelled between the EG120 third-party observation and the EG140 official posting floor. |
| EG140 | Associate Director | Associate Director, M3 to M4 | The best-evidenced grade in the ladder because BMS posts the title in several markets.Current BMS postings including Tampa at $161,250 to $195,391 and Warsaw Biostatistics at PLN430,190 to PLN521,293. |
| EG150 | Director | Director, M4 | Posted ranges vary by state; the San Diego posting sits above the New Jersey reference.Current San Diego Director posting at $227,418 to $275,577, discounted to the Princeton reference market. |
| EG160 | Senior Director | Senior Director, M5 | Equity rather than base becomes the main lever from this grade upward.Current Seattle Senior Director posting at $218,870 to $291,727, discounted to the Princeton reference market. |
| EG170 | Executive Director | Executive Director, one layer below Vice President | Officer status can start here, which introduces performance and market share units.Posted senior-leader ranges extended by the modelled equity ladder; no BMS grant matrix is published. |
| EG180 | Vice President | Vice President, below the corporate officer layer | The last grade below the proxy-disclosed officer population; not itself disclosed.Aggregator observations for the Vice President title plus the modelled long-term incentive ladder below the named executive layer. |
Critical evidence warning
Bristol Myers Squibb does not publish salary bands, minimums or midpoints for ordinary employees anywhere in the reviewed sources, and its enterprise-grade codes appear in public job material only at EG80 and EG90. Every figure at EG100 and above that is not backed by a posted range is a third-party observation or a calibrated model around one, and should be used for orientation rather than quoted as a BMS pay band.
Compensation by Band — Princeton
Low / median / high annual values at 1.00× base and 1.00× total-compensation factors versus Princeton. Total equals base plus bonus plus annualized equity.
| Band | Title | Base | Variable | Total TC | Equity |
|---|---|---|---|---|---|
| EG80 | Analyst / Specialist / Associate 0–2 years · reported | $70K – $94K | 8% | $89K $75K – $102K | — |
| EG90 | Senior Analyst / Senior Specialist / Associate Scientist 2–5 years · verified | $85K – $115K | 10% | $112K $95K – $129K | $2K |
| EG100 | Lead / Analyst III / Manager 4–7 years · reported | $104K – $140K | 12% | $142K $120K – $163K | $5K |
| EG110 | Manager II / Associate Manager / Principal Specialist 6–9 years · reported | $119K – $161K | 15% | $171K $145K – $197K | $10K |
| EG120 | Senior Manager 8–12 years · reported | $131K – $177K | 15% | $197K $168K – $227K | $20K |
| EG130 | Senior Manager II / Group Lead 10–14 years · modeled | $146K – $198K | 18% | $235K $200K – $270K | $32K |
| EG140 | Associate Director 11–16 years · verified | $153K – $207K | 20% | $261K $222K – $300K | $45K |
| EG150 | Director 14–19 years · verified | $187K – $253K | 25% | $350K $298K – $403K | $75K |
| EG160 | Senior Director 17–22 years · verified | $212K – $286K | 30% | $444K $377K – $510K | $120K |
| EG170 | Executive Director 20+ years · modeled | $249K – $337K | 35% | $621K $527K – $714K | $225K |
| EG180 | Vice President 20+ years · modeled | $265K – $359K | 45% | $952K $810K – $1.10M | $500K |
Total Compensation Range by Band
Total compensation in Princeton across the employee bands. Ranges are planning envelopes around the median, not offer bands.
Global Footprint & Pay Arbitrage
Bristol Myers Squibb reported approximately 32,500 employees in 43 countries at 31 December 2025, about 54 percent in the United States excluding Puerto Rico. Princeton, New Jersey is the pay anchor. India is modelled from directly observed local salaries rather than a United States multiplier, and every other market is a cost-of-labour factor applied to the Princeton median.
Office and market catalogue — calibration factors versus Princeton
| Location | Likely office profile | Presence | Base | TC |
|---|---|---|---|---|
Princeton United States · USD | Headquarters, corporate functions and research and development | Official site directory and current job postings | 1.00× | 1.00× |
Lawrenceville United States · USD | Corporate functions and research and development | Official site directory and current job postings | 1.00× | 1.00× |
New Brunswick United States · USD | Research, development and operations | Official site directory; the highest visa filing concentration | 1.00× | 1.00× |
Summit United States · USD | Cell therapy manufacturing and corporate functions | Official site directory and current job postings | 1.01× | 1.01× |
Cambridge United States · USD | Massachusetts research and development | Official site directory and current job postings | 1.05× | 1.04× |
Devens United States · USD | Biologics manufacturing with a science and operations role mix | Official site directory and current job postings | 0.98× | 0.98× |
Seattle United States · USD | Cell therapy, digital and research and development | Current Senior Director posting at $218,870 to $291,727 | 1.05× | 1.04× |
San Diego United States · USD | Research and development | Current Director posting at $227,418 to $275,577 | 1.08× | 1.07× |
Redwood City United States · USD | Specialised Bay Area research and development | Official site directory; limited direct band evidence | 1.12× | 1.10× |
Tampa United States · USD | Business services, digital and capability centre | Current Associate Director posting at $161,250 to $195,391 | 0.88× | 0.90× |
Phoenix United States · USD | Commercial and corporate functions | Official site directory; limited direct pay evidence | 0.91× | 0.92× |
Manatí Puerto Rico · USD | Pharmaceutical manufacturing and quality | Official site directory; a US dollar market with local labour rules | 0.70× | 0.72× |
Hyderabad India · INR | Innovation, technology, analytics and research capability hub | Strongest public India hub evidence; Levels.fyi and 6figr observations | 0.16× | 0.16× |
Bangalore India · INR | Technology, data and commercial support | Hyderabad benchmark plus a 2 percent metro adjustment | 0.16× | 0.16× |
Mumbai India · INR | Commercial and corporate functions | Hyderabad benchmark plus a 4 percent metro adjustment | 0.17× | 0.17× |
Uxbridge United Kingdom · GBP | Commercial, medical and corporate functions | Associate Director and Director anchors at £85,635 to £118,752 | 0.74× | 0.76× |
Chester United Kingdom · GBP | Business services centre | BMS states the site has more than 350 employees; no public pay scale | 0.66× | 0.68× |
Cambridge United Kingdom · GBP | Research and development and scientific roles | Modelled from the Uxbridge anchor with a scientific-market adjustment | 0.72× | 0.74× |
Dublin Ireland · EUR | Corporate, supply chain and commercial functions | Junior and scientific anchors available; senior levels modelled | 0.68× | 0.70× |
Boudry Switzerland · CHF | International operations and research and development | Associate Director observations at CHF195,000 to CHF272,000; small sample | 1.12× | 1.16× |
Munich Germany · EUR | Commercial, medical and corporate functions | Official country presence; no comprehensive band disclosure | 0.78× | 0.81× |
Rueil-Malmaison France · EUR | Commercial, medical and corporate functions | Official country presence; employer social costs excluded from cash pay | 0.79× | 0.83× |
Madrid Spain · EUR | Commercial and medical affairs | Official country presence; planning estimate only | 0.63× | 0.66× |
Milan Italy · EUR | Commercial and medical affairs | Official country presence; planning estimate only | 0.66× | 0.70× |
Warsaw Poland · PLN | Biostatistics, data science and shared services | Official Associate Director Biostatistics range of PLN430,190 to PLN521,293 | 0.58× | 0.61× |
Tokyo Japan · JPY | Japan headquarters, commercial and medical affairs | Official country headquarters; no BMS-specific band data is public | 0.72× | 0.75× |
Shanghai China · CNY | Commercial, clinical and medical affairs | Senior Medical Manager observations at CN¥693,000 to CN¥751,000 | 0.50× | 0.52× |
Singapore Singapore · SGD | Regional headquarters, supply chain and commercial functions | Associate Director annualised average of S$219,684 | 0.86× | 0.88× |
Melbourne Australia · AUD | Australia headquarters at Mulgrave, commercial and medical affairs | Associate Director and Business Unit Director anchors; very small sample | 0.70× | 0.71× |
Toronto Canada · CAD | Commercial, medical and corporate functions | Official country presence; limited direct band data | 0.83× | 0.86× |
BMS does not publish city-level headcount, so this catalogue cannot rank sites by employee count. The only site-level figures disclosed anywhere in the sources are more than 350 employees at Chester in the United Kingdom and approximately 246 Australian employees in a 2025 modern-slavery statement, more than three quarters of them at the Melbourne headquarters.
Princeton anchor medians — the basis of every modeled cell
| Band | Base | Stock | Bonus | Total |
|---|---|---|---|---|
| EG80 | $82K | $0 | $7K | $89K |
| EG90 | $100K | $2K | $10K | $112K |
| EG100 | $122K | $5K | $15K | $142K |
| EG110 | $140K | $10K | $21K | $171K |
| EG120 | $154K | $20K | $23K | $197K |
| EG140 | $180K | $45K | $36K | $261K |
| EG150 | $220K | $75K | $55K | $350K |
| EG160 | $249K | $120K | $75K | $444K |
- The Princeton column is the anchor. EG140 through EG160 come from current BMS Workday postings discounted to the New Jersey reference market, EG100 and EG120 from Indeed manager and senior manager averages of $119,162 and $153,972, and EG90 from official job material naming the grade.
- New Jersey is the reference market at a factor of 1.00, covering Princeton, Lawrenceville, New Brunswick and Warren. Cambridge, Seattle, San Diego and the Bay Area carry scientific and cost-of-labour premiums between 5 and 12 percent, while Tampa, Phoenix, Syracuse and Puerto Rico are discounted by 9 to 30 percent.
- India is not a client-delivery offshore model. Hyderabad is positioned as an innovation, technology, analytics and research hub, so its column uses directly observed Indian rupee salaries with Bangalore and Mumbai carrying 2 and 4 percent metro adjustments rather than a flat United States multiplier.
- India total compensation runs at roughly 16 percent of the Princeton anchor at EG80 and rises towards 48 percent at EG180, while base pay rises from 16 percent to 74 percent over the same span. Base and total therefore carry separate calibration factors that change with seniority.
- Named executive pay comes from the SEC Summary Compensation Table and is never generated from the band model. The Senior Vice President and Executive Vice President layer is deliberately excluded from the band ladder so that a single global officer figure cannot drag every city factor towards parity at the top.
Model rules
- Every modeled cell is the Princeton median multiplied by the city base or total factor and then by the 24 August 2026 XE foreign-exchange snapshot. A single snapshot is used for every currency.
- Total compensation here is base plus target annual incentive plus annualised equity only. The source bundle added a notional employer benefit load of roughly 12 percent of base in the United States and 15 percent in India; that is employer cost rather than pay and has been stripped, so every total in this report reconciles to its own components.
- City factors come from the bundle's own calibration, which anchors on official postings in Tampa, San Diego, Seattle and Warsaw and on third-party observations in Hyderabad, Uxbridge, Melbourne, Boudry, Singapore and Shanghai.
- India carries separate base and total factors and separate top-of-ladder factors, because Indian base pay converges on the anchor much faster than Indian total compensation does. Every other market shows a flat ratio across the ladder and therefore carries a single factor.
- Sign-on awards, make-whole grants, relocation, severance, shift premiums, sales commissions, tax equalisation, mobility premiums and employer payroll taxes are excluded everywhere. Where no direct city observation exists the cell is marked modeled and should be read as a planning envelope.
Variable Pay & Annual Cash Incentive
Bristol Myers Squibb discloses its executive annual incentive formula in full and discloses nothing about the employee bonus grid. The named executive targets, metric weights and Company Performance Factor below are company disclosures; the band targets are a modelled planning benchmark reconstructed from posted role material and third-party salary records.
| Band | Target | Mechanism | Recent payout |
|---|---|---|---|
EG80 Analyst / Specialist / Associate | 8% of base | Annual target bonus. Company, function or business and individual performance may all affect the payout. | Not publicly disclosed |
EG90 Senior Analyst / Senior Specialist / Associate Scientist | 10% of base | Annual target bonus. Company, function or business and individual performance may all affect the payout. | Not publicly disclosed |
EG100 Lead / Analyst III / Manager | 12% of base | Annual target bonus. Company, function or business and individual performance may all affect the payout. | Not publicly disclosed |
EG110 Manager II / Associate Manager / Principal Specialist | 15% of base | Annual target bonus. Company, function or business and individual performance may all affect the payout. | Not publicly disclosed |
EG120 Senior Manager | 15% of base | Annual target bonus with a functional delivery component in most business and operations roles. | Not publicly disclosed |
EG130 Senior Manager II / Group Lead | 18% of base | Annual target bonus with a functional delivery component in most business and operations roles. | Not publicly disclosed |
EG140 Associate Director | 20% of base | Annual target bonus with a business or portfolio delivery component. Posted ranges quote base only, so the bonus sits on top of the advertised number. | Not publicly disclosed |
EG150 Director | 25% of base | Annual target bonus weighted towards business-unit or therapeutic-area outcomes. | Not publicly disclosed |
EG160 Senior Director | 30% of base | Annual target bonus weighted towards enterprise and function outcomes rather than individual delivery. | Not publicly disclosed |
EG170 Executive Director | 35% of base | Annual target bonus on enterprise outcomes. Officer status at this level can bring the disclosed executive framework into scope. | Not publicly disclosed |
EG180 Vice President | 45% of base | Annual target bonus on enterprise outcomes, running on the same metric set as the disclosed executive plan for officers in scope. | Not publicly disclosed |
Executive incentive targets — percent of salary
Named-executive outcomes
| Executive | Target | Paid | Attainment |
|---|---|---|---|
| Christopher S. Boerner | $2,381,317 | $3,754,684 | 157.66% of target |
| David V. Elkins | $1,141,231 | $1,799,484 | 157.66% of target |
| Adam Lenkowsky | $1,138,217 | $1,794,732 | 157.66% of target |
| Greg Meyers | $1,058,630 | $1,669,036 | 157.66% of target |
| Cristian Massacesi | $419,178 | $660,876 | 157.66% of a prorated target |
Employee payout timing and history
Do not equate the executive Company Performance Factor with every employee's payout. Awards below the officer layer can carry business, function and individual modifiers, local target schedules and eligibility rules that are not publicly disclosed anywhere in the reviewed sources. There is no published bonus target by grade, so the 8 percent at EG80 rising to 45 percent at EG180 shown here is a modelled planning benchmark rather than BMS policy, and no employee-wide payout history exists.
Sales and special incentives
Sales commission plans, quota structures, accelerators, draws, project incentives, deal bonuses, spot awards and manufacturing shift premiums are all Not publicly disclosed. Commercial roles in the model carry the same modelled targets as their grade peers, which will understate on-target earnings for quota-carrying representatives and district managers, particularly in the United States and in the high-commission commercial markets.
Equity — RSUs, PSUs, Options & ESPP
Bristol Myers Squibb is a United States issuer, so employee equity means restricted stock units rather than an Indian-style employee stock ownership plan. Legal eligibility is unusually broad — approximately 27,200 employees were annually eligible and about 22,800 received a 2025 award — but no grade-by-grade entitlement matrix is published, and no employee stock purchase plan was found in any reviewed source.
- The 85 million-share reserve was newly approved in May 2026, and no post-approval utilisation percentage was disclosed in the reviewed materials. Dividing historical grant volume by the new reserve would be misleading, so no utilisation figure is quoted here.
- The three-year average burn rate was disclosed at below 0.71 percent and total potential overhang at 5.9 percent using the company's own stated denominator. Both are company disclosures rather than calculations made in this report.
- At the $67.92 share price used for illustration the full 85 million-share reserve is worth about $5.77 billion. That is neither an accounting fair value nor expected immediate dilution; it is a scale marker only.
- About 22,800 of approximately 27,200 annually eligible employees received a 2025 award, roughly 84 percent. Broad eligibility is a plan characteristic, not an entitlement to a grant, and the split of awards by grade or country is Not publicly disclosed.
Equity plan capacity and grant activity
Vesting — common reported employee schedule
BMS states that employee restricted stock units generally vest ratably over three or four years, so the four-year ladder above is the longer of the two disclosed patterns and a three-year ratable schedule is equally common. Recurring named executive performance and market share units use a three-year cliff instead: the March 2026 grants vest in full on 10 March 2029. Earlier grants used different schedules, so the individual grant agreement always controls. Non-employee director deferred share units are generally deferred until board service ends.
Eligibility by hierarchy level
- Eligibility is broad and incidence is selective. The plan covers employees, officers, directors and other service providers, but BMS publishes no minimum grade for a grant, no standard award table and no guarantee that an eligible employee receives an award in any year.
- Award type is the clearest public hierarchy rule. Restricted stock units are the instrument for the general employee population, while recurring named executive long-term incentive is 60 percent performance share units and 40 percent market share units.
- Performance share units run a three-year performance cycle and can settle anywhere from 0 to 200 percent of target. Market share units are linked to BMY share-price performance, so both instruments carry outcome risk that a plain restricted stock unit does not.
- No executive option grants were reported for 2023 through 2025 even though the plan permits options and stock appreciation rights, so options should not be modelled as part of a current BMS package.
- Illustrative annualised grant values used in this report run from zero at EG80 to about $2,000 at EG90, $20,000 at EG120, $45,000 at EG140, $120,000 at EG160 and $500,000 at EG180. These are a planning model built from employee reports of roughly $4,000 to $5,000 awards in some 2025 cases at the lower grades, not a disclosed grant matrix.
Indicative annual grant value by band — Princeton
| Band | Annual value (USD) | Median | Shares at $67.92 |
|---|---|---|---|
| EG90 | $2K – $3K | $2K | ~22–37 |
| EG100 | $4K – $6K | $5K | ~55–92 |
| EG110 | $8K – $13K | $10K | ~110–184 |
| EG120 | $15K – $25K | $20K | ~221–368 |
| EG130 | $24K – $40K | $32K | ~353–589 |
| EG140 | $34K – $56K | $45K | ~497–828 |
| EG150 | $56K – $94K | $75K | ~828–1,380 |
| EG160 | $90K – $150K | $120K | ~1,325–2,208 |
| EG170 | $169K – $281K | $225K | ~2,485–4,141 |
| EG180 | $375K – $625K | $500K | ~5,521–9,202 |
Annualized planning value (±25%), not the face value of every new-hire grant. Share equivalents use the $67.92 reference price at 25 August 2026 close and ignore plan valuation rules and PSU performance. Highlighted rows are disclosed grant-date stock awards.
Named executive target equity
| Executive | Target | Units / structure |
|---|---|---|
Christopher S. Boerner Board Chair and Chief Executive Officer | $16.06M of 2025 stock awards | Recurring long-term incentive of 60 percent performance share units and 40 percent market share units. The 10 March 2026 grant was 156,735 performance share units plus 104,490 market share units on a three-year cliff to 10 March 2029, worth about $17.74 million at the $67.92 illustrative price. |
Adam Lenkowsky Executive Vice President and Chief Commercialization Officer | $6.14M of 2025 stock awards | The 10 March 2026 grant was 48,980 performance share units plus 32,653 market share units on the same three-year cliff, worth about $5.54 million at the $67.92 illustrative price. |
Cristian Massacesi Executive Vice President, Chief Medical Officer and Head of Development | $7.85M of 2025 stock awards | The largest 2025 stock figure after the chief executive despite a partial-year salary, which is consistent with a make-whole or new-hire component on top of the recurring award. |
David V. Elkins Executive Vice President and Chief Financial Officer | $5.98M of 2025 stock awards | Recurring performance and market share unit mix. No 2026 grant Form 4 was captured for him in the reviewed filings. |
Greg Meyers Executive Vice President and Chief Digital and Technology Officer | $4.21M of 2025 stock awards | The smallest named executive stock award for 2025, on the same 60 percent performance and 40 percent market share unit design. |
Executive Compensation
2025 Summary Compensation Table values from the 2026 proxy statement. The stock column is a grant-date accounting value rather than cash realised, and the two diverge sharply for packages the company itself describes as 92 percent at risk for the chief executive and about 85 percent at risk for the other named executives.
Reading the package
Salary was 7.25 percent of the chief executive's 2025 reported total, stock awards 73.41 percent, the non-equity incentive 17.16 percent and other compensation 2.18 percent. The proxy describes the target package as 92 percent at risk and 80 percent long-term incentive, so the reported figure turns on performance share unit certification and the BMY share price rather than on salary. The other named executives run at generally 85 percent at risk and 70 percent long-term incentive.
Peer totals use each company's own proxy methodology and are not perfectly comparable. Grant-date stock valuation, pension accounting, sign-on awards and fiscal timing can each move a ranking by several million dollars. On these figures Christopher S. Boerner sits fourth of five, below AbbVie, Pfizer and Amgen and above Merck, in a large-cap pharmaceutical set where every package is dominated by performance-linked equity.
Named Executive Officers & Board
The named executive team is stable at the top but was refreshed in the medical and development function during 2025, and the whole group is being paid through a multi-year cost programme that has removed roughly 1,600 net roles since the end of 2024.
Cristian Massacesi's 2025 row is the one that needs care. His $388,462 salary is a partial year, his $1,125,000 cash bonus is a separate award rather than an annual incentive payout, and his $7,853,994 stock figure is the second largest in the table despite the short service period. That pattern is consistent with a make-whole or new-hire component, and the proxy confirms that sign-on and make-whole awards can materially change first-year compensation for strategic hires. Executive salary changes for 2025 took effect on 1 April 2025, recurring long-term incentive was granted in early March and annual incentives were paid in March following year-end.
Board compensation framework
| Element | Amount | Notes |
|---|---|---|
| Annual cash retainer | $110,000 | Paid to each non-employee director under the disclosed 2025 policy. The employee Board Chair receives no director pay. |
| Annual equity award | $210,000 in deferred share units | Delivered as deferred share units that are generally deferred until board service ends rather than as restricted stock or options. |
| Committee chair and lead director retainers | Additional to the base retainer | Amounts by committee are disclosed in the proxy but were not captured individually in the reviewed extract. |
| Independent Board Chair | About $413,721 in 2025 | Peter R. Dolan as then independent Board Chair; Theodore R. Samuels received about $355,000. |
| Typical full-year director total | About $320,000 | Most directors who served the full year landed near this figure on the combined cash and deferred share unit package. |
| Plan cap on director pay | $600,000, or $900,000 for the Chair or Lead Director | The 2026 Stock Award and Incentive Plan caps total annual non-employee director compensation, subject to plan terms. |
Director compensation is a governance package rather than an employment band and is deliberately excluded from the band chart. No stock options were granted to directors, and Christopher S. Boerner received no separate non-employee director compensation while serving as both Chief Executive Officer and Board Chair.
Regional heads and other officers
The proxy identifies named executive officers and corporate officers but publishes no compensation table for regional presidents, the Chief Human Resources Officer, the General Counsel, the Company Secretary or any other functional leader. Compensation for those roles is Not publicly disclosed and is visible only through Section 16 share movements where the individual is a reporting person. No enterprise-grade code is published for officers either, which is why this report stops the band ladder at Vice President.
Insider Trades — SEC Forms 3/4/5
Bristol Myers Squibb is NYSE-listed, so the governing record is SEC Section 16 Forms 3, 4 and 5 rather than any Indian exchange filing. No promoter or SAST disclosure applies. Open-market purchases and sales are economically different from grants and vesting events, so the two are kept separate below.
| Date | Person | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-01 | David V. Elkins EVP and Chief Financial Officer | Sale 25,519 shares at $61.60 and 4,481 at $62.05 under a Rule 10b5-1 plan adopted 3 June 2025. | 30,000 | $61.67 | $1.85M |
| 2026-03-10 | Christopher S. Boerner Board Chair and Chief Executive Officer | Award 104,490 market share units plus 156,735 performance share units on a three-year cliff to 10 March 2029; value shown at the $67.92 illustrative price, not grant-date accounting value. | 261,225 | — | $17.74M |
| 2026-03-10 | Adam Lenkowsky EVP and Chief Commercialization Officer | Award 32,653 market share units plus 48,980 performance share units on the same three-year cliff to 10 March 2029. | 81,633 | — | $5.54M |
| 2025-09-02 | David V. Elkins EVP and Chief Financial Officer | Sale Weighted-average sale price reported under a Rule 10b5-1 plan. | 56,000 | $47.33 | $2.65M |
| 2025-02-20 | Christopher S. Boerner Board Chair and Chief Executive Officer | Purchase Open-market purchase with no Rule 10b5-1 plan; 104,626 shares held directly after the transaction. | 2,000 | $55.05 | $110K |
Reading guide
Benefits & Perks
Benefits are considerably better evidenced than pay at Bristol Myers Squibb, because the company runs country careers and rewards pages even though it publishes no salary scale. Every row below comes from an official BMS page or a named government rule, and rows that rest on statutory minima are marked as such rather than presented as BMS policy.
United States
- Retirement — 401(k) with a dollar-for-dollar company match up to 6 percent of eligible pay. Plan materials also describe an additional age and service-based company contribution. The plan document governs vesting, eligible compensation and the age and service formula. [official]
- Medical — Medical, pharmacy, dental and vision options. Fertility and family-building support and mental-health resources are described alongside the core plans. Employee premium contributions and plan tiers are not published. [official]
- Leave — Flexible time off for most exempt employees. Non-exempt employees receive at least four weeks of vacation plus holidays, sick time and a year-end company closure. [official]
- Family — Parental and caregiver leave. Offered alongside dependent-care accounts and backup care support. The exact week counts by leave type are not published on the public careers pages. [official]
- Savings and protection — Health and flexible spending accounts, disability, life and travel insurance. Commuter benefits and tuition assistance complete the package. Amounts and caps vary by plan year and are not published. [official]
Global programs
- Growth — LinkedIn Learning and structured leadership-development programmes. Described consistently across the United States, United Kingdom, Ireland and Australia careers pages, so it reads as a global rather than a country programme. [official]
- Growth — Tuition support or reimbursement in several markets. Subject to eligibility and approval, and reimbursed up to 100 percent at company discretion in Australia. The United States equivalent is described as tuition assistance. [official]
- Wellbeing — Employee Assistance Program, wellbeing and recognition programmes. Recurring themes across every country careers page reviewed, alongside volunteer opportunities and internal mobility. [official]
- Working model — Hybrid eligibility is role and site dependent. The United Kingdom page quantifies it at up to 50 percent home working where the role allows. Manufacturing and laboratory work remains substantially site-based everywhere. [official]
- Equity — Broad annual equity eligibility. Approximately 27,200 employees were annually eligible and about 22,800 received a 2025 award. There is no employee stock purchase plan in any reviewed source. [official]
Benefit fields not publicly quantified
The India gap list is the longest: the insurer, medical sum insured, family-floater design, group term life amount, earned, sick and casual leave day counts, paternity weeks, employer National Pension System contribution, phone and internet allowance, relocation bands and any education-reimbursement cap are all Not publicly disclosed. Ireland pension and private health employer contribution levels, BMS-specific Australian health subsidies, additional leave and car allowances, and every Continental European, Japanese, Chinese, Singaporean and Canadian benefit term sit in the same category. These are recorded as undisclosed rather than filled in from unrelated employers.
Performance Review & Pay Progression
Bristol Myers Squibb discloses its executive review calendar in the proxy and discloses almost nothing about the process that applies to everyone else. Executive salary changes for 2025 took effect on 1 April 2025, recurring long-term incentive was granted in early March and annual incentives were paid in March after year-end. The enterprise-wide merit calendar below that layer is not published.
Not publicly disclosed
Modeled promotion planning timeline
| Band | Years to next scope | Promotion hike | Status |
|---|---|---|---|
| EG80 | 1.5–3 years to EG90 | Not disclosed | Modeled planning interval |
| EG90 | 2–4 years to EG100 or EG110 | Not disclosed | Modeled planning interval |
| EG100 | 2–4 years to EG110 | Not disclosed | Modeled planning interval |
| EG110 | 2–4 years to EG120 | Not disclosed | Modeled planning interval |
| EG120 | 2.5–5 years to EG130 | Not disclosed | Modeled planning interval |
| EG130 | 2.5–5 years to EG140 | Not disclosed | Modeled planning interval |
| EG140 | 3–5 years to EG150 | Not disclosed | Modeled planning interval |
| EG150 | 3–6 years to EG160 | Not disclosed | Modeled planning interval |
| EG160 | 3–6 years to EG170 | Not disclosed | Modeled planning interval |
| EG170 | 4–7 years to EG180 | Not disclosed | Modeled planning interval |
| EG180 | Variable; the move to Senior Vice President is a corporate officer appointment | Not disclosed | Modeled planning interval |
Off-cycle adjustments can occur for promotion, expanded responsibility, retention or market correction, but BMS publishes no standard percentage schedule for any of them. Public evidence supports cost reduction and role elimination rather than a broad salary cut or a formal enterprise pay freeze: no reviewed source records either. Restructuring is the complication that matters most for progression, because management-layer reduction and site consolidation can shrink the number of open roles even while selected hubs such as Hyderabad and the new Houston-area campus expand.
Pay progression evidence
Modelled progression, not BMS policy: EG80 to EG90 typically takes 1.5 to 3 years for an 8 to 15 percent base increase; EG90 to EG110 takes 2 to 4 years for 10 to 18 percent; EG120 to EG140 takes 2.5 to 5 years for 12 to 22 percent; and EG150 and above takes 3 to 6 or more years for 15 to 30 percent plus an equity recalibration. These are transparent planning assumptions included so the ladder is usable, and they should never be represented as BMS policy. Equity recalibration rather than base pay becomes the dominant lever from Associate Director upward, where annualised stock moves from roughly 17 percent of the package at EG140 to 52 percent at EG180.
H-1B / LCA Visa Footprint — United States
Bristol Myers Squibb is a steady mid-volume H-1B sponsor concentrated in New Jersey, filing for scientists, biostatisticians and programmers, data and technology staff, engineers, quality specialists and business roles. Labour condition application wages are guaranteed base salary only, so they exclude the annual incentive, restricted stock units and every benefit, and should never be compared with a total compensation figure.
Dataset summary
| Dataset | Result | Interpretation |
|---|---|---|
| H1B Salary Lookup combined dataset | 214 certified FY2025 to FY2026 records at a $148,703 median | The 25th percentile was $131,741 and the 75th percentile $165,000. This is the only extract that publishes quartiles for the company as a whole. |
| MyVisaJobs employer profile | 247 FY2025 applications at a $154,159 average offered base | Also the source for the USCIS petition outcomes, the FY2026 run rate and the historical worksite concentration. Updated 18 August 2026. |
| H1BGrader FY2026 legal-name subset | 63 records at a $166,187 average and a $163,984 median | A much smaller record count than MyVisaJobs for an overlapping period, because the legal-name filter and the fiscal-year window differ. |
| H1BData.info FY2025 filter | Record-level FY2025 extract used for worksite cross-checks | Period and filter inconsistencies against the other extracts were material enough that the figures are kept separate rather than merged. |
City-level H-1B wage history
| City | P25 | Median | P75 | Records |
|---|---|---|---|---|
All BMS worksites The only company-wide extract that publishes quartiles. Certified Department of Labor labour condition application records for FY2025 and FY2026 combined, base salary only. | $132K | $148,703 | $165K | 214 |
Lawrenceville, New Jersey The highest worksite median in the dataset, consistent with a corporate and research role mix. Quartiles are reconstructed from the company-wide spread, not published. | $140K | $158,496 | $176K | 95 |
Princeton, New Jersey The headquarters worksite and the largest record count. The median and the count use different windows in the source, so the pairing is directional. Quartiles are reconstructed. | $122K | $138,000 | $153K | 241 |
New Brunswick, New Jersey The only city-level extract with published quartiles, covering FY2022 through FY2025. Guaranteed base salary only. | $125K | $136,000 | $152K | 119 |
Tampa, Florida The business services and digital hub, and the clearest geographic discount in the visa data after Devens. Quartiles are reconstructed from the company-wide spread. | $114K | $128,123 | $142K | 24 |
Devens, Massachusetts The lowest worksite median, reflecting a biomanufacturing and science role mix rather than a low local labour market. Quartiles are reconstructed. | $90K | $101,336 | $112K | 76 |
All-years aggregates. P25/P75 are rounded reconstruction values marked modeled; medians and record counts are the stronger fields.
Selected title / worksite records
| Title | Worksite | Proffered wage | Notes |
|---|---|---|---|
| Company-wide middle 50 percent | All BMS worksites, FY2025 to FY2026 certified records | $131,741 to $165,000 around a $148,703 median | A narrow band by large-employer standards, consistent with a filing mix concentrated in mid-career scientific and technical roles rather than entry-level positions. |
| New Jersey corridor concentration | Princeton, Lawrenceville and New Brunswick | 455 of the captured worksite records | The three New Jersey sites dominate the filing base, which matches the reference-market treatment of New Jersey at a 1.00 calibration factor throughout this report. |
| Manufacturing and science discount | Devens, Massachusetts | $101,336 median across 76 records | About 32 percent below the Lawrenceville median. The gap is a role-mix effect rather than a Massachusetts cost-of-labour effect; the Cambridge site carries a premium factor in the same state. |
| Business services discount | Tampa, Florida | $128,123 median across 24 records | About 14 percent below the company-wide median, and consistent with the 0.88 Tampa base factor derived independently from the current Associate Director posting. |
| FY2025 petition outcomes | United States, all worksites | 240 approvals against 7 denials on 247 petitions | A 97.2 percent approval rate. Filing counts are not employee counts: amendments, extensions and duplicate legal-name records all inflate the totals. |
| Common filing families | All BMS worksites, historical aggregate | Scientists, biostatistics and programming, data and technology, engineering, quality and business roles | The source does not publish a ranked title count for BMS, so the families are listed without individual filing volumes rather than being assigned invented numbers. |
Reading the data correctly
- Labour condition application wages are guaranteed base salary. They exclude the annual incentive, restricted stock units, sign-on payments and every benefit, which together are a large part of any BMS package at Associate Director and above.
- Quartiles for Lawrenceville, Princeton, Tampa and Devens are reconstructed from the company-wide spread rather than published by the Department of Labor, so they are analytical estimates and are labelled as such on each row.
- The Princeton median and record count come from different windows in the source, so the pairing is directional rather than a single consistent sample.
- The public extracts disagree materially because they apply different legal-name filters, fiscal-year windows and status categories. A $148,703 median, a $154,159 average and a $166,187 subset average all describe the same employer over overlapping periods.
- A labour condition application is a filing, not a hire. Certified applications exceed petitions, and petitions exceed actual employees. Use the Department of Labor and USCIS source files for anything legal or audit related, preserving the exact legal entity, fiscal year and worksite filter.
Key Nuances & Insights
Approximately 27,200 employees were annually eligible and about 22,800 received a 2025 award. That is genuinely broad, but BMS publishes no grade-by-grade entitlement matrix, and employee reports of roughly $4,000 to $5,000 awards at the lower grades sit alongside no award at all for others at the same level. Predictability rises with seniority rather than being guaranteed by it.
EG80 and EG90 have public clues in official job material; every mapping above that is employee-reported and the sources conflict. Where BMS posts a salary range, as it does in several United States states and in Poland, the posted range should control and the grade code should be ignored entirely.
The proxy describes the chief executive target package as 92 percent at risk and 80 percent long-term incentive, and the other named executives as generally 85 percent at risk and 70 percent long-term incentive. Salary was 7.25 percent of the 2025 chief executive total, so the reported number is an accounting valuation rather than money received.
The 2025 cash Company Performance Factor reached 157.66 percent while the completed 2022 to 2024 performance share unit award settled at 63.12 percent of target. Reading one as a proxy for the other is the single most common error available in this disclosure, and the two measure different periods on different metrics.
Hyderabad is an innovation, technology, analytics and research hub rather than a client-billing delivery organisation, so the conventional onshore-offshore framing does not apply. Scarce digital, analytics and clinical skills can command substantial premiums over broad Indian market averages, and the compression against Princeton narrows from roughly six times at EG80 to close to two times at EG180.
Tampa sits about 12 percent below the New Jersey reference for a like title on the current Associate Director posting, while San Diego, Seattle and the Bay Area carry premiums of 5 to 12 percent. This is one of the few large pharmaceutical employers where the geographic spread can be read directly from live job advertisements rather than inferred.
Cristian Massacesi's 2025 row shows a $388,462 partial-year salary alongside $7,853,994 of stock and a separate $1,125,000 cash bonus. The proxy confirms that sign-on and make-whole awards materially change first-year compensation for strategic hires. Comparable mechanisms below the named executive layer exist but are not disclosed.
Headcount fell from about 34,100 at year-end 2024 to about 32,500 at year-end 2025 under a productivity programme targeting $2 billion of savings by the end of 2027, and a New Jersey WARN disclosure covered 247 roles across staged 2026 dates. Management-layer reduction and site consolidation shrink the number of open roles even while Hyderabad and the new Houston-area campus expand.
Nothing in the 10-K, the proxy or any BMS careers page describes a discounted share purchase scheme. Employees below the officer layer have no disclosed route to buy BMY shares at a discount, so the entire equity opportunity depends on a discretionary restricted stock unit award landing in a given year.
The 85 million-share 2026 plan reserve was approved in May 2026 and no post-approval utilisation percentage has been published. Dividing historical grant volume by the new reserve produces a number that looks precise and means nothing.
Social charges in France and Belgium, superannuation in Australia, pension in Ireland and statutory provident fund in India can make two equal base salaries economically very different. The source model added an employer benefit load of roughly 12 to 15 percent of base to every total; that load has been stripped from every figure in this report.
The source model covered Argentina, Colombia, Brazil and Mexico. Argentina in particular becomes stale within weeks of any foreign-exchange snapshot, which is why this report keeps only the markets where a static conversion remains defensible and drops the rest rather than publishing figures that will mislead.
Research control
Christopher S. Boerner's $21.88 million sits fourth of five in this large-cap pharmaceutical comparison, below AbbVie at $32.53 million, Pfizer at $27.58 million and Amgen at $24.69 million, and above Merck at $20.11 million. The 131:1 pay ratio is markedly lower than the technology-sector norm, largely because the BMS median employee is paid $166,523 against a global workforce that is 46 percent international and heavily weighted towards research, manufacturing and commercial roles rather than software engineering. On the employee side the EG80 to EG180 ladder tracks the large-cap biopharmaceutical market closely, with the equity share of the package rising from zero at entry to 52 percent at Vice President.
Evidence classification
| Label | Meaning | Examples and permitted use |
|---|---|---|
| Verified | A BMS filing, an official BMS careers or benefits page, an official BMS job posting or a government rule. | Executive pay, the pay ratio, equity plan mechanics, benefits, headcount, the EG90 grade, the Associate Director, Director and Senior Director posted ranges and the foreign-exchange snapshot. |
| Reported | A named third-party dataset with observable records, chiefly Indeed, Levels.fyi, Glassdoor, 6figr and the visa aggregators. | The EG100 and EG120 Princeton anchors, the Hyderabad, Uxbridge, Melbourne, Boudry, Singapore and Shanghai observations, and every H-1B wage distribution. |
| Modeled | The Princeton anchor multiplied by a city calibration factor and the foreign-exchange snapshot, inside a plus or minus 15 percent planning envelope for base and total and 25 percent for equity. | The EG130, EG170 and EG180 rows, and every city cell without a direct observation. |
| Not publicly disclosed | No source in the research bundle supports a figure. | Recorded as such rather than estimated, most heavily across the performance-review process and the India, European and Asia Pacific benefit terms. |
Explicit “Not publicly disclosed” index
Known gaps and diligence before relying on a cell
- 1The Senior Vice President and Executive Vice President cohort is deliberately excluded from the band ladder and carried in the executive section only. Including it would have anchored the top of the location interpolation on a single global officer figure and pushed every offshore market towards parity at the top of the ladder, which is exactly the distortion that produces an Indian officer priced on a United States officer base. The ladder therefore ends at EG180 Vice President with a seniority of 11.
- 2The source model computed total compensation as base plus target incentive plus annualised equity plus a notional employer benefit load of roughly 12 percent of base in the United States and 15 percent in India. That load is employer cost rather than pay, so every total in this report has been rebuilt from its own components and no figure here matches the source bundle's headline totals. The Princeton EG140 total is $261,000 here against $283,000 in the bundle for exactly this reason.
- 3India's geographic compression is convex rather than linear. Observed Indian base pay runs at 16 percent of the Princeton anchor at EG80, about 27 percent at EG120 and 74 percent at EG180, but the report engine interpolates linearly by seniority between the junior and senior factors. That overstates modelled Indian base pay in the EG110 to EG130 range by up to roughly 45 percent against the observed local medians, and the observed figures should be preferred over the interpolated cells in that window. Indian total compensation fits the linear interpolation closely and needs no such caveat.
- 4Only one research bundle exists for this company, so there is no second model to cross-check against. Where the bundle itself flags conflicting evidence, chiefly the EG100 to EG180 grade mapping and the Princeton H-1B median and record count coming from different windows, the conflict is preserved rather than resolved.
- 5The visa extracts disagree materially. H1B Salary Lookup gives a $148,703 median across 214 combined FY2025 and FY2026 records, MyVisaJobs a $154,159 FY2025 average across 247 filings, and H1BGrader a $166,187 average across a 63-record FY2026 legal-name subset. Each is preserved separately rather than averaged, and city quartiles outside New Brunswick are reconstructed from the company-wide spread.
- 6Named executive annual incentive targets are not stated as percentages anywhere in the reviewed extract. The 150 percent chief executive and 100 percent other-officer targets shown here are implied by dividing the disclosed payouts by the disclosed 157.66 percent Company Performance Factor, and are labelled as implied throughout.
- 7Committee chair and lead director retainer amounts are disclosed in the proxy but were not captured in the reviewed extract, so the board table names the retainer without a value rather than estimating one.
- 8BMS discloses no geographic revenue split in any reviewed source, so the regional revenue panel is omitted entirely rather than repurposed to show something else.
- 9The source model priced 54 markets including Argentina, Colombia, Brazil, Mexico, New Zealand, South Korea, Hungary, the Czech Republic, the Nordics, Belgium, the Netherlands and the United Arab Emirates. This report keeps 30 markets where a static foreign-exchange conversion remains defensible and where the source recorded a traceable factor, and drops the high-inflation and thinnest-evidence markets rather than publishing figures that will be stale or unsupportable.
- 10The 2024 year-end headcount of about 34,100 includes acquired workforces as well as organic movement, so the 2023 to 2024 rise and the 2024 to 2025 fall are not a clean like-for-like series.
- 11No companywide salary hike percentage, pay freeze, salary cut, campus offer revision or off-cycle correction schedule was located in any source, for either 2025 or 2026.
FX rates used — 1 USD equals, snapshot 2026-08-24
Single-date conversion layer for comparability; it ignores payroll-date FX, tax, purchasing power, benefits valuation and hedging. Compensation intelligence, not legal, tax, investment, immigration or employment advice.
Source register — 16 sources
| 10-K FY2025 | Bristol Myers Squibb Annual Report on Form 10-K for the year ended 31 December 2025 · United States Securities and Exchange Commission · 2025-12-31. Headcount, country coverage, revenue, human capital reporting, restructuring and stock compensation disclosure. |
| DEF 14A 2026 | Bristol Myers Squibb 2026 Definitive Proxy Statement · United States Securities and Exchange Commission · 2026-03-25. Executive pay, the pay ratio, the annual incentive formula and Company Performance Factor, director pay and equity plan detail. |
| 2026 Plan approval | 2026 annual meeting of shareholders and Stock Award and Incentive Plan approval · Bristol Myers Squibb · 2026-05-05. Approval of the 85 million-share 2026 Stock Award and Incentive Plan. |
| Forms 4 | Section 16 filings for Bristol Myers Squibb insiders · United States Securities and Exchange Commission · 2026-08-26. Open-market purchases and sales, 2026 performance and market share unit grants, and Rule 10b5-1 plan references. |
| BMS Workday | Current Bristol Myers Squibb job postings · Bristol Myers Squibb · 2026-08-26. Enterprise-grade clues at EG80 and EG90 and posted base ranges in Tampa, San Diego and Seattle. |
| Warsaw posting | Associate Director, Biostatistics, Warsaw, requisition R1598666 · Bristol Myers Squibb · 2026-08-26. The official PLN430,190 to PLN521,293 base range that anchors the senior Polish grades. |
| BMS Careers | Bristol Myers Squibb United States, United Kingdom, Ireland, Australia and India careers and benefits pages · Bristol Myers Squibb · 2026-08-26. Retirement, medical, leave, family, learning and hybrid-working terms, plus the Chester site headcount. |
| Indeed | Bristol Myers Squibb salary pages · Indeed · 2026-08-26. United States manager and senior manager averages of $119,162 and $153,972, and the Singapore Associate Director annualised average. |
| Levels.fyi | Bristol Myers Squibb compensation profiles · Levels.fyi · 2026-08-26. United States reported total compensation and the Hyderabad Software Engineer II median of ₹15.87 lakh base and ₹18.43 lakh total. |
| Glassdoor | Bristol Myers Squibb salary estimates · Glassdoor · 2026-08-26. India Senior Manager, United Kingdom Associate Director, Melbourne, Boudry and Shanghai observations. |
| 6figr | Bristol Myers Squibb India salary profiles · 6figr · 2026-08-26. Small-sample Hyderabad manager profiles at ₹40.3 lakh base and ₹45.4 lakh total; single observation, low confidence. |
| H-1B extracts | H1B Salary Lookup, MyVisaJobs, H1BData.info and H1BGrader Bristol Myers Squibb extracts · Third-party Department of Labor and USCIS aggregators · 2026-08-26. Certified labour condition application percentiles, application and petition counts, approval rates and worksite medians. |
| Reuters | Strategic productivity initiative and restructuring coverage · Reuters and Bristol Myers Squibb results releases · 2026-04-30. Layoff programmes, the $1.5 billion and $2 billion savings targets and progress against them. |
| BMS Newsroom | Announcement of a $2.3 billion facility in Texas · Bristol Myers Squibb · 2026-08-10. The Houston-area campus investment and the nearly 500 skilled jobs it is expected to create. |
| FX snapshot | Historical United States dollar currency table · XE · 2026-08-24. Every local currency conversion in this report, on a single snapshot date. |
| Statutory sources | Australian Taxation Office, Fair Work Ombudsman, GOV.UK and the Employees' Provident Fund Organisation · Government publishers · 2026-08-26. The 12 percent superannuation guarantee, National Employment Standards leave, United Kingdom auto-enrolment and holiday minima, and Indian provident fund and gratuity rules. |
Recent News & Workforce Trend
Bristol Myers Squibb is cutting cost and investing in selected capabilities at the same time. There is no companywide salary action in any reviewed source, but there is a multi-year productivity programme, a New Jersey WARN filing and a $2.3 billion new campus, and all three change the promotion and hiring picture more than any pay announcement would.
The 2024 rise and the 2025 fall are not a clean like-for-like series, because the 2024 increase reflects acquisition and integration effects on top of organic hiring. Site-level quarterly headcount and voluntary attrition are Not publicly disclosed anywhere, so the only geographic signal in the filings is the roughly 54 to 46 split between the United States excluding Puerto Rico and the rest of the world.
The company said the investment would create nearly 500 skilled jobs, with construction employment much larger during build-out. It is the clearest counterweight to the restructuring programme in the current news set.
Reuters reported that about $1 billion of the expanded savings programme had been delivered, with further operating-model simplification underway. Fewer management layers means fewer promotion slots.
Chief executive total compensation of $21,879,919 against a $166,523 median employee, with a 157.66 percent Company Performance Factor driving the cash incentive.
Christopher S. Boerner received 156,735 performance share units and 104,490 market share units, and Adam Lenkowsky 48,980 and 32,653 respectively, all vesting 10 March 2029.
A WARN-related disclosure covered 247 roles across staged dates in 2026, continuing the multi-year restructuring programme in the company's reference pay market.
Headcount declined from approximately 34,100 at year-end 2024 while revenue reached $48.194 billion and the strategic productivity initiative continued.
The company targeted an additional $2 billion of annualised savings by the end of 2027. The number of incremental job reductions was not specified at announcement.
The programme targeted about $1.5 billion of savings by the end of 2025 through portfolio prioritisation, fewer management layers and site consolidation.